Skip To Main Content
Upal Basu Roy on Muck Rack

Upal Basu Roy

As seen in: MDPI, Becker's Hospital Review, Healio, HemOnc Today, Future Medicine, OncLive, Archives of Pathology, Oncology Central, CONQUER
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Upal Basu

Contact Upal Basu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Effects of Space Flight on Inflammasome Activation in the Brain of Mice

|
By Upal Basu Roy, Roey Hadad, Angel Rodriguez, Ángel Rodríguez, Alen Saju
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Tumor-treating fields extend OS in metastatic NSCLC

|
By Mark Leiser Verified, Mindy Valcarcel, Upal Basu Roy, Rebecca S. Heist
| HemOnc Today Verified
Perspective Back to Top Rebecca Heist, MD, MPH The changing standard-of-care landscape really poses challenges for clinical trial design. By 2016, at the time of study start, immune checkpoint inhibition was known to be superior to docetaxel in the second-line setting. By 2018, immune checkpoint inhibition had moved to the first-line treatment setting in lung cancer. We currently do not use immune checkpoint inhibition as was used in this study.
Open in Who Shared Issue with article?

Osimertinib after surgery reduces risk for death by 51% in resected

|
By Matthew Shinkle Verified, Devin McLaughlin, Upal Basu Roy, Joshua K. Sabari
| HemOnc Today Verified
Source/Disclosures Source: Herbst RS, et al. Abstract LBA3. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: AstraZeneca funded this study.
Open in Who Shared Issue with article?
See all 25 licensed articles (27 Total)